A Trial of SHR-1701 in Combination With and Without Famitinib Malate in Patients With Extensive Stage Small Cell Lung Cancer
The study is being conducted to evaluate the efficacy and safety of SHR-1701 in combination with or without famitinib malate for the treatment of extensive stage small cell lung cancer after the failure of previous systemic chemotherapy
Lung Cancer
DRUG: SHR-1701ï¼› Famitinib|DRUG: SHR-1701
Objective response rate (ORR) based on RECIST 1.1 criteria, up to approximately 1 year.
Progression free survival (PFS) based on RECIST 1.1 criteria, up to approximately 1 year.|Disease control rate (DCR) based on RECIST 1.1 criteria, up to approximately 1 year.|Duration of response (DoR), up to approximately 1 year|Overall survival (OS), up to approximately 1 year|AEs+ SAEs determined by NCI-CTCAE V5.0, Baseline until up to 90 days after end of treatment.
The study is being conducted to evaluate the efficacy and safety of SHR-1701 in combination with or without famitinib malate for the treatment of extensive stage small cell lung cancer after the failure of previous systemic chemotherapy